5% Minoxidil + 2% Minoxidil
Phase 3Completed 0 views this week 0 watching⚡ Active
Interest: 40/100
40
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Alopecia
Conditions
Alopecia
Trial Timeline
Jun 1, 2010 → Feb 1, 2012
NCT ID
NCT01145625About 5% Minoxidil + 2% Minoxidil
5% Minoxidil + 2% Minoxidil is a phase 3 stage product being developed by Johnson & Johnson for Alopecia. The current trial status is completed. This product is registered under clinical trial identifier NCT01145625. Target conditions include Alopecia.
What happened to similar drugs?
1 of 19 similar drugs in Alopecia were approved
Approved (1) Terminated (0) Active (18)
Hype Score Breakdown
Clinical
17
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01145625 | Phase 3 | Completed |
Competing Products
20 competing products in Alopecia
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Baricitinib | Eli Lilly | Phase 2 | 42 |
| CTP-543 | Sun Pharmaceutical | Phase 2/3 | 42 |
| CTP-543 | Sun Pharmaceutical | Phase 3 | 40 |
| Deuruxolitinib + Placebo | Sun Pharmaceutical | Phase 3 | 47 |
| Baricitinib + Placebo | Eli Lilly | Phase 2/3 | 38 |
| Baricitinib 4 MG Oral Tablet | Eli Lilly | Approved | 47 |
| Baricitinib + Placebo | Eli Lilly | Phase 3 | 47 |
| Baricitinib + Placebo | Eli Lilly | Phase 3 | 40 |
| minoxidil | Johnson & Johnson | Phase 3 | 40 |
| Minoxidil + vehicle of 5% Minoxidil topical foam | Johnson & Johnson | Phase 2 | 35 |
| 5% Minoxidil Topical Foam + Vehicle Topical Foam | Johnson & Johnson | Phase 3 | 40 |
| Upadacitinib + Upadacitinib Placebo | AbbVie | Phase 3 | 47 |
| Upadacitinib + Placebo | AbbVie | Phase 3 | 47 |
| Secukinumab + Placebo | Novartis | Phase 2 | 27 |
| Daxdilimab | Amgen | Phase 2 | 35 |
| Ritlecitinib | Pfizer | Pre-clinical | 30 |
| LITFULO | Pfizer | Pre-clinical | 30 |
| Ritlecitinib | Pfizer | Pre-clinical | 33 |
| Ritlecitinib higher dose + Ritlecitinib lower dose + Placebo | Pfizer | Phase 3 | 47 |
| Ritlecitinib | Pfizer | Pre-clinical | 26 |